Does Cramer's recommendation focus on specific stocks?

Cramer did not name specific stocks but highlighted the sector's overall exceptional activity.

How has the FDA leadership change affected biotech?

Cramer did not provide specifics but indicated the change was a key factor in recent sector moves.

Should investors sell semiconductor stocks for biotech?

Cramer did not recommend that; he urged attention to biotech opportunities without abandoning other investments.

Jim Cramer: Biotech Is the Hottest Group in the Market Right Now

Jim Cramer of CNBC highlighted biotech as the market's hottest group, moving beyond the usual semiconductor and hyperscaler focus. He attributed the shift partly to the change in FDA leadership.

July 9, 2026

2 min read

Source: 24/7 Wall St.

In a notable shift from the usual focus on semiconductor and hyperscaler stocks, CNBC's Jim Cramer directed investors' attention to the biotech sector, calling it "the hottest group" in the market right now.

Details

Cramer noted a significant move in biotech that has not been widely discussed, describing it as extraordinary, especially following the change in leadership at the U.S. Food and Drug Administration (FDA). He emphasized that the sector is experiencing unprecedented activity.

Context

This statement comes at a time when major biotech stocks like Eli Lilly (LLY) and Amgen (AMGN) are performing strongly, while semiconductor stocks like NVIDIA (NVDA) remain in the spotlight. Cramer believes investors may be overlooking opportunities in this sector.

What This Means for Investors

Investors should monitor regulatory developments at the FDA, as leadership changes could impact drug approval timelines. The strong performance of biotech stocks may offer diversification opportunities beyond traditional technology.

Frequently Asked Questions

Cramer pointed to an extraordinary move in the sector, particularly after the FDA leadership change.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.